Intimation under Regulation 30 of SEBI Listing Regulations, 2015 w.r.t resignation of Dr. S Prasad from the position of CEO of the Company.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts less than Nifty Microcap 250 and 0.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr. S Prasad has resigned as Chief Executive Officer of Pharmaids Pharmaceuticals Limited with effect from the close of business hours on August 7, 2025. The resignation is attributed to personal reasons, as stated in his letter to the Board. Consequently, Dr. Prasad will also cease to be a Key Managerial Personnel (KMP) of the company. The disclosure has been made under Regulation 30 of the SEBI (LODR) Regulations, 2015, with the required details and resignation letter enclosed. No replacement has been announced in this filing.
The sudden exit of the CEO, even for personal reasons, may create short-term leadership uncertainty at Pharmaids Pharmaceuticals. Shareholders should watch for an announcement regarding an interim or permanent CEO appointment, as prolonged absence at the top could affect strategic continuity.